The use of asymmetric distributions in average bioequivalence

Generic drugs have been commercialized in numerous countries. Most of these countries approve the commercialization of a generic drug when there is evidence of bioequivalence between the generic drug and the reference drug. Generally, the pharmaceutical industry is responsible for the bioequivalence...

Full description

Saved in:
Bibliographic Details
Published in:Statistics in medicine 2016-07, Vol.35 (15), p.2525-2542
Main Authors: de Souza, Roberto Molina, Achcar, Jorge Alberto, Martinez, Edson Zangiacomi, Mazucheli, Josmar
Format: Article
Language:English
Subjects:
Asymmetry
average bioequivalence
Bayes Theorem
Bayesian inference
Commercialization
copula functions
Data Interpretation, Statistical
Drugs, Generic
extended generalized gamma distribution
Generic drugs
Humans
multivariate skew-t distribution
Probability distribution
Statistical analysis
Statistical Distributions
Therapeutic Equivalency
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Generic drugs have been commercialized in numerous countries. Most of these countries approve the commercialization of a generic drug when there is evidence of bioequivalence between the generic drug and the reference drug. Generally, the pharmaceutical industry is responsible for the bioequivalence test under the supervision of a regulatory agency. This procedure is concluded after a statistical data analysis. Several agencies adopt a standard statistical analysis based on procedures that were previously established. In practice, we face situations in which this standard model does not fit to some sets of bioequivalence data. In this study, we propose an evaluation of bioequivalence using univariate and bivariate models based on an extended generalized gamma distribution and a skew‐t distribution, under a Bayesian perspective. We introduce a study of the empirical power of hypothesis tests for univariate models, showing advantages in the use of an extended generalized gamma distribution. Three sets of bioequivalence data were analyzed under these new procedures and compared with the standard model proposed by the majority of regulatory agencies. In order to verify that the asymmetrical distributions are usually better fitted for the data, when compared with the standard model, model discrimination methods were used, such as the Deviance Information Criterion (DIC) and quantile–quantile plots. The research concluded that, in general, the use of the extended generalized gamma distribution may be more appropriate to model bioequivalence data in the original scale. Copyright © 2016 John Wiley & Sons, Ltd.
ISSN:0277-6715
1097-0258
DOI:10.1002/sim.6885